

Pembrolizumab KEYNOTE-407

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Reviewed, but not qualified for an ESMO-MCBS credit



Serious and disabling adverse effects



Other adjustments



Long-term plateau in the survival

Pembrolizumab KEYNOTE-407

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies

Therapeutic Indication: First-line metastatic squamous non-small cell lung cancer

Experimental Arm: Pembrolizumab + Carboplatin + either paclitaxel or nab-paclitaxel

Control Arm: Placebo + carboplatin + either paclitaxel or nab-paclitaxel



